| Literature DB >> 23462680 |
Grazia Arpino1, Daniele Generali2, Anna Sapino3, Lucia Del Matro4, Antonio Frassoldati5, Michelino de Laurentis6, Paolo Pronzato4, Giorgio Mustacchi7, Marina Cazzaniga8, Sabino De Placido6, Pierfranco Conte5, Mariarosa Cappelletti9, Vanessa Zanoni9, Andrea Antonelli9, Mario Martinotti2, Fabio Puglisi10, Alfredo Berruti11, Alberto Bottini2, Luigi Dogliotti11.
Abstract
Gene expression profiling tests are used in an attempt to determine the right treatment for the right person with early-stage breast cancer that may have spread to nearby lymph nodes but not to distant parts of the body. These new diagnostic approaches are designed to spare people who do not need additional treatment (adjuvant therapy) the side effects of unnecessary treatment, and allow people who may benefit from adjuvant therapy to receive it. In the present review we discuss in detail the major diagnostic tests available such as MammaPrint dx, Oncotype dx, PAM50, Mammostrat, IHC4, MapQuant DX, Theros-Breast Cancer Gene Expression Ratio Assay, and their potential clinical applications.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23462680 DOI： 10.1016/j.breast.2013.01.016
Source DB: PubMed Journal: Breast ISSN： 0960-9776 Impact factor: 4.380